摘要
目的对比非霍奇金淋巴瘤患者在利妥昔单抗联合化疗前后淋巴细胞亚群的变化。方法于2011年1月至2018年11月期间纳入作者所在医院行利妥昔单抗联合化疗的非霍奇金淋巴瘤患者58例,为观察组;同期纳入健康者30例为对照组。对比化疗前后非霍奇金淋巴瘤患者与对照组淋巴细胞亚群中NK细胞、Treg、CD^8+、CD^4+、CD 3+;根据病理类型将观察组患者分为B-NHL患者和T-NHL患者,对比2组患者化疗后上述淋巴细胞亚群指标;根据治疗效果分为有效组和无效组,对比2组患者化疗前后上述淋巴细胞亚群。结果①化疗前观察组NK细胞、CD^4+、CD 3+较对照组低(P<0.05);CD^8+、Treg较对照组高(P<0.05)。化疗后,观察组NK细胞、CD^4+、CD 3+升高,其中NK细胞仍显著低于对照组(P<0.05);CD^8+、Treg显著降低且仍然高于对照组(P<0.05)。②化疗后B-NHL患者NK细胞、Treg均较T-NHL低,CD^8+、CD^4+、CD 3+较T-NHL高,差异有统计学意义,P<0.05。③有效组和无效组在化疗前K细胞、Treg、CD^8+、CD^4+、CD 3+比较,P>0.05;有效组化疗后与无效组化疗后相比,前者Treg、CD^4+、CD 3+更高(P<0.05),而NK细胞、CD^8+比较差异无统计学意义(P>0.05)。结论非霍奇金淋巴瘤患者细胞免疫功能低下,不同病理类型患者T细胞亚群和NK细胞表达有所不同,且T细胞亚群和NK细胞表达与化疗效果有关。利妥昔单抗联合化疗能一定程度改善患者免疫功能,通过观察患者治疗前后淋巴细胞亚群水平能辅助疗效预判。
Objective To compare the changes of lymphocyte subsets in patients with non-Hodgkin's lymphoma before and after rituximab combined with chemotherapy.Methods 58 patients with non-Hodgkin's lymphoma who received rituximab combined with chemotherapy were included in the observation group;30 healthy subjects were included in the control group.NK cells,Treg,CD^8+,CD^4+,and CD 3+were compared in the lymphocyte subsets of patients with non-Hodgkin's lymphoma before and after chemotherapy.The patients in the observation group were divided into B-NHL patients and T-NHL patients according to the pathological type.The above-mentioned lymphocyte subsets were measured after chemotherapy in the 2 groupS;the effective and ineffective groups were divided according to the therapeutic effect,and the lymphocyte subsets before and after chemotherapy were compared between the 2 groups.Results①The NK cells,CD^4+and CD 3+in the observation group were lower than those of the control group before the chemotherapy(P<0.05);CD^8+and Treg were higher than the control group(P<0.05).After chemotherapy,NK cells,CD^4+and CD 3+were elevated in the observation group,and NK cells were still significantly lower than the control group(P<0.05);CD^8+and Treg were significantly lower than the control group(P<0.05).②After chemotherapy,NK cells and Treg were lower in T-NHL than in T-NHL,and CD^8+,CD^4+and CD 3+were higher than T-NHL,the difference was statistically significant(P<0.05).③The effective group and the ineffective group were compared before chemotherapy with K cells,Treg,CD8,CD^4+,CD 3+(P>0.05);Compared with the ineffective group,the effective group had higher Treg,CD^4+,and CD 3+,(P<0.05)but there was no significant difference between NK cells and CD^8+(P>0.05).Conclusion The cellular immune function of patients with non-Hodgkin's lymphoma is low.The expression of T cell subsets and NK cells are different in different pathological types,and the expression of T cell subsets and NK cells is related to chemotherapy effect.Rituximab combi nation Chemotherapy can improve the cellular immune function to a certain extent,and can predict the efficacy by observing the level of lymphocyte subsets before and after treatment.
作者
陈慧
陈会慧
徐浩
谌廷妹
张婧
CHEN Hui;CHEN Huihui;XU Hao(The Fourth Affiliated Hospital of Nantong University,Yancheng,224001)
出处
《实用癌症杂志》
2020年第2期339-342,共4页
The Practical Journal of Cancer
